HLB Therapeutics Co.,Ltd. (KOSDAQ:115450)
3,510.00
-145.00 (-3.97%)
Aug 8, 2025, 3:30 PM KST
SolarWinds Revenue
HLB Therapeutics had revenue of 15.05B KRW in the quarter ending March 31, 2025, with 17.97% growth. This brings the company's revenue in the last twelve months to 57.22B, up 2.19% year-over-year. In the year 2024, HLB Therapeutics had annual revenue of 54.93B with 4.45% growth.
Revenue (ttm)
57.22B
Revenue Growth
+2.19%
P/S Ratio
5.15
Revenue / Employee
1.19B
Employees
48
Market Cap
294.76B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 54.93B | 2.34B | 4.45% |
Dec 31, 2023 | 52.59B | 10.19B | 24.03% |
Dec 31, 2022 | 42.40B | -1.18B | -2.72% |
Dec 31, 2021 | 43.59B | 656.63M | 1.53% |
Dec 31, 2020 | 42.93B | -16.04B | -27.20% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Samsung Biologics | 4,898.69B |
Celltrion | 3,662.23B |
ALTEOGEN | 151.65B |
SK Biopharmaceuticals | 578.00B |
Yuhan | 2,114.76B |
Peptron | 4.30B |
HLB Co., Ltd. | 74.64B |
PharmaResearch | 392.31B |